Kei Kishimoto
Company: Selecta Bioscience
Job title: Chief Scientific Officer
Seminars:
PANEL Q&A: An Overview & Assessment of Current & Future Strategies to Circumvent or Lessen the Innate & Early Adaptive Immune Response to Gene Therapy 12:30 pm
day: Re-Dosing Discussion Day
Mitigation Of AAV Vector Immunogenicity With Tolerogenic Immtor Nanoparticles 11:30 am
ImmTOR nanoparticles encapsulating rapamycin induce antigen-specific immune tolerance Enhancement of liver-directed transgene expression observed at both initial and repeat doses of AAV vectors ImmTOR nanoparticles currently in Phase 3 trials with an immunogenic uricase enzyme therapy for the treatment of refractory goutRead more
day: Re-Dosing Discussion Day